IDXX News and Press, IDEXX Laboratories Inc. From 05/17/22

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. The market was very weak in the quarter for a plethora of reasons. The Fed is in a tough position, as it needs to sig...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Outperformance of the Fund’s investments in Communication Services, Financials, and Industrials and lower exposure...

IDEXX Laboratories (NASDAQ:IDXX) stock has lost 6.5% to $384.78 in Thursday afternoon trade, after the veterinary services company reported a mixed set of Q1 2022 earnings and cut its FY 2022 guidance for both revenue and non-GAAP EPS. IDXX reported Q1 non-GAAP EPS of $2.24 which missed ...

IDEXX Laboratories (NASDAQ:IDXX) has extended the post-earnings losses to the second straight session on Thursday after Bank of America lowered its rating on the animal health company to Neutral from Buy following its lackluster 1Q 2022 results. While the stock trades at a fair valuation...

Image source: The Motley Fool. Idexx Laboratories (NASDAQ: IDXX) Q1 2022 Earnings Call May 04, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Idexx Laboratories (IDXX) Q1 2022 Earnings Call Transcript

IDEXX Laboratories, Inc. (IDXX) Q1 2022 Earnings Conference Call May 04, 2022, 08:30 ET Company Participants Brian McKeon - CFO, EVP & Treasurer Jonathan Mazelsky - President, CEO & Director Conference Call Participants Christopher Schott - JPMorgan Chase & Co Michael Ryskin - Ban...

IDEXX Laboratories (NASDAQ:IDXX -10.6%) stock falls after the company posted lower-than-expected Q1 profit and revised its 2022 revenue forecast, that were below wall street estimates.  The company now expects 2022 revenue to be between $3.39B - $3.46B vs. consensus estimate of $3.5...

IDEXX Laboratories press release (NASDAQ:IDXX): Q1 Non-GAAP EPS of $2.24 misses by $0.01. Revenue of $836.54M (+7.6% Y/Y) in-line. Re-calibrated 2022 revenue outlook of $3.39B-$3.46B vs consensus of $3.54B reflects 5.5% - 8% reported growth and 7.5% - 10% organic Updated EPS outlook of $8.11 ...

IDEXX Laboratories (NASDAQ:IDXX) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is $2.25 (+7.7% Y/Y) and the consensus Revenue Estimate is $838.66M (+7.8% Y/Y). Over the last 1 year, IDXX has beaten EPS estimates 100% of the ...